Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2019
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung T Le, Vincent J Picozzi, Andrew H Ko, et al.
The New England Journal of Medicine
|
March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2018
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
John Heymach, Lada Krilov, Anthony Alberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 10, 2020
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome
Manish A Shah, Peter Enzinger, Andrew H Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2020
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Takahiro Tsujikawa, Todd Crocenzi, Jennifer N Durham, et al.
JAMA Oncology
|
September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma
Eileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman, et al.
JAMA Oncology
|
March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Margaret A Tempero, Uwe Pelzer, Eileen M O'Reilly, et al.
The Lancet. Oncology
|
January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2019
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung T Le, Vincent J Picozzi, Andrew H Ko, et al.
The New England Journal of Medicine
|
March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2018
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
John Heymach, Lada Krilov, Anthony Alberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 10, 2020
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome
Manish A Shah, Peter Enzinger, Andrew H Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2020
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Takahiro Tsujikawa, Todd Crocenzi, Jennifer N Durham, et al.
JAMA Oncology
|
September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma
Eileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman, et al.
JAMA Oncology
|
March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Margaret A Tempero, Uwe Pelzer, Eileen M O'Reilly, et al.
The Lancet. Oncology
|
January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Page
of 10